Gene mutations in lung cancer: Promising predictive factors for the success of molecular therapy

被引：25
作者：
Inoue, A [1 ]
Nukiwa, T [1 ]
机构：
[1] Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Sendai, Miyagi 980, Japan
来源：
PLOS MEDICINE | 2005年 / 2卷 / 01期
关键词：
D O I：
10.1371/journal.pmed.0020013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：20 / 22
页数：3
相关论文
共 12 条
  • [1] Novel targets for lung cancer therapy: Part II
    Dy, GK
    Adjei, AA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) : 3016 - 3028
  • [2] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    Fukuoka, M
    Yano, S
    Giaccone, G
    Tamura, T
    Nakagawa, K
    Douillard, JY
    Nishiwaki, Y
    Vansteenkiste, J
    Kudoh, S
    Rischin, D
    Eek, R
    Horai, T
    Noda, K
    Takata, I
    Smit, E
    Averbuch, S
    Macleod, A
    Feyereislova, A
    Dong, RP
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
  • [3] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
    Giaccone, G
    Herbst, RS
    Manegold, C
    Scagliotti, G
    Rosell, R
    Miller, V
    Natale, RB
    Schiller, JH
    von Pawel, J
    Pluzanska, A
    Gatzemeier, M
    Grous, J
    Ochs, JS
    Averbuch, SD
    Wolf, MK
    Rennie, P
    Fandi, A
    Johnson, DH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 777 - 784
  • [4] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
    Herbst, RS
    Giaccone, G
    Schiller, JH
    Natale, RB
    Miller, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 785 - 794
  • [5] K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer:: a combined analysis of 881 cases
    Huncharek, M
    Muscat, J
    Geschwind, JF
    [J]. CARCINOGENESIS, 1999, 20 (08) : 1507 - 1510
  • [6] Severe acute interstitial pneumonia and gefitinib
    Inoue, A
    Saijo, Y
    Maemondo, M
    Gomi, K
    Tokue, Y
    Kimura, Y
    Ebina, M
    Kikuchi, T
    Moriya, T
    Nukiwa, T
    [J]. LANCET, 2003, 361 (9352) : 137 - 139
  • [7] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
    Kris, MG
    Natale, RB
    Herbst, RS
    Lynch, TJ
    Prager, D
    Belani, CP
    Schiller, JH
    Kelly, K
    Spiridonidis, H
    Sandler, A
    Albain, KS
    Cella, D
    Wolf, MK
    Averbuch, SD
    Ochs, JJ
    Kay, AC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158
  • [8] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, TJ
    Bell, DW
    Sordella, R
    Gurubhagavatula, S
    Okimoto, RA
    Brannigan, BW
    Harris, PL
    Haserlat, SM
    Supko, JG
    Haluska, FG
    Louis, DN
    Christiani, DC
    Settleman, J
    Haber, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139
  • [9] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
    Paez, JG
    Jänne, PA
    Lee, JC
    Tracy, S
    Greulich, H
    Gabriel, S
    Herman, P
    Kaye, FJ
    Lindeman, N
    Boggon, TJ
    Naoki, K
    Sasaki, H
    Fujii, Y
    Eck, MJ
    Sellers, WR
    Johnson, BE
    Meyerson, M
    [J]. SCIENCE, 2004, 304 (5676) : 1497 - 1500
  • [10] KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    Pao, W
    Wang, TY
    Riely, GJ
    Miller, VA
    Pan, QL
    Ladanyi, M
    Zakowski, MF
    Heelan, RT
    Kris, MG
    Varmus, HE
    [J]. PLOS MEDICINE, 2005, 2 (01) : 57 - 61
12